Glen Frick1,2, Brian Yan1, Lenard A Adler3. 1. Shire, Lexington, MA, USA. 2. Endo Pharmaceuticals, Malvern, PA, USA. 3. New York University, New York, NY, USA.
Abstract
Objective: Evaluate the efficacy and tolerability of triple-bead mixed amphetamine salts (MAS) in ADHD. Method: Adults with ADHD Rating Scale IV (ADHD-RS-IV) total scores ≥32 were randomized to 6 weeks of triple-bead MAS (25, 50, or 75 mg) or placebo. The primary endpoint was ADHD-RS-IV total score change from baseline at end of study (EOS). Results: Least squares mean (95% confidence interval [CI]) treatment differences for ADHD-RS-IV total score changes from baseline to EOS significantly favored triple-bead MAS (all doses combined: -10.6 [-13.2, -8.0]; p < .0001); there were no significant differences between triple-bead MAS dosages. The most frequently reported TEAEs with triple-bead MAS (all doses combined) included insomnia, decreased appetite, and dry mouth. Mean ± SD pulse and systolic blood pressure increases at EOS were 3.5 ± 10.33 bpm and 0.3 ± 10.48 mmHg with triple-bead MAS (all doses combined). Conclusion: Triple-bead MAS significantly reduced adult ADHD symptoms; the safety profile was consistent with previous triple-bead MAS studies.
Objective: Evaluate the efficacy and tolerability of triple-bead mixed amphetamine salts (MAS) in ADHD. Method: Adults with ADHD Rating Scale IV (ADHD-RS-IV) total scores ≥32 were randomized to 6 weeks of triple-bead MAS (25, 50, or 75 mg) or placebo. The primary endpoint was ADHD-RS-IV total score change from baseline at end of study (EOS). Results: Least squares mean (95% confidence interval [CI]) treatment differences for ADHD-RS-IV total score changes from baseline to EOS significantly favored triple-bead MAS (all doses combined: -10.6 [-13.2, -8.0]; p < .0001); there were no significant differences between triple-bead MAS dosages. The most frequently reported TEAEs with triple-bead MAS (all doses combined) included insomnia, decreased appetite, and dry mouth. Mean ± SD pulse and systolic blood pressure increases at EOS were 3.5 ± 10.33 bpm and 0.3 ± 10.48 mmHg with triple-bead MAS (all doses combined). Conclusion: Triple-bead MAS significantly reduced adult ADHD symptoms; the safety profile was consistent with previous triple-bead MAS studies.
Entities:
Keywords:
efficacy; safety and tolerability; triple-bead mixed amphetamine salts
Authors: Matthew Brams; Ann C Childress; Michael Greenbaum; Ming Yu; Brian Yan; Margo Jaffee; Brigitte Robertson Journal: J Child Adolesc Psychopharmacol Date: 2017-08-17 Impact factor: 2.576
Authors: Richard H Weisler; Michael Greenbaum; Valerie Arnold; Ming Yu; Brian Yan; Margo Jaffee; Brigitte Robertson Journal: CNS Drugs Date: 2017-08 Impact factor: 5.749
Authors: Tim L Wigal; Jeffrey H Newcorn; Nelson Handal; Sharon B Wigal; Ioulietta Mulligan; Virginia Schmith; Eric Konofal Journal: CNS Drugs Date: 2018-03 Impact factor: 5.749
Authors: Jesse Elliott; Amy Johnston; Don Husereau; Shannon E Kelly; Caroline Eagles; Alice Charach; Shu-Ching Hsieh; Zemin Bai; Alomgir Hossain; Becky Skidmore; Eva Tsakonas; Dagmara Chojecki; Muhammad Mamdani; George A Wells Journal: PLoS One Date: 2020-10-21 Impact factor: 3.240